Key Stats for CLDX Stock
- Price Change for CLDX stock: +24%
- CLDX Share Price as of Feb. 25: $31
- 52-Week High: $31
- CLDX Stock Price Target: $53
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Celldex Therapeutics (CLDX) stock jumped more than 24% on February 25 after the company announced key clinical progress. The rally followed confirmation that Celldex completed enrollment in its Phase 3 barzolvolimab trials for chronic spontaneous urticaria. That update came just one day before the company reported quarterly results.
While Celldex reported minimal revenue and a wider quarterly net loss, investors focused on pipeline momentum. Reuters reported Q4 revenue of about $0.1 million and a net loss of roughly $81 million.
The clinical milestone appeared to outweigh near-term financial losses.
The timing also mattered because the update came ahead of multiple scientific and investor conferences. Upcoming data presentations helped drive renewed interest in the stock.
See analysts’ growth forecasts and price targets for CLDX stock (It’s free!) >>>
What the Market Is Telling Us About CLDX Stock
The sharp move suggests investors are prioritizing late-stage clinical progress over current earnings. Celldex remains a clinical-stage biotech, so profitability metrics remain deeply negative. Gross and operating margins reflect ongoing R&D investment rather than commercial scale.
However, the company maintains a strong balance sheet with net cash of roughly $581 million. That liquidity supports continued development without near-term financing pressure. As a result, balance sheet strength has become a key tailwind.
Market sentiment also reflects optimism around barzolvolimab’s broad potential across inflammatory diseases. Still, outcomes remain dependent on clinical and regulatory execution.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Celldex Therapeutics, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CLDX, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CLDX alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Celldex Therapeutics stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
